From Early Development to Commercial Readiness: Real-World Lessons in Advancing Lentiviral-Based Therapies

Join VIVEbiotech together with its partners Kiji Therapeutics and Genewity for an interactive panel exploring how lentiviral vector-based therapies are advancing across the full development pathway—from early-stage innovation to clinical and commercial readiness.
The session will feature real-world insights from ongoing programs, including the clinical advancement iPSC-MSC engineered cell therapies for the treatment of broad range of inflammatory diseases such as GvHD, as well as the progression of a gene therapy program for Severe Combined Immunodeficiency (SCID) preparing for regulatory submission and commercial phase.
Following brief introductory remarks, the panel will focus on key challenges such as vector design, process development, scaling for GMP manufacturing, and aligning early decisions with regulatory and commercialization requirements.
Lunch will be served during this session.